Please assess the completion status of the following clinical trial:

Trial Title: A Study of N-Acetyl Cysteine in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients between 3.0 and 12.11 years of age inclusive~2. Males and females who are physically healthy~3. diagnosis of autism based Diagnostic and Statistical Manual (DSM-IV-TR) criteria, the Autism Diagnostic Interview-Revised, and expert clinical evaluation~4. Clinical Global Impression Severity rating of 4~5. Care provider who can reliably bring subject to clinic visits, can provide trustworthy ratings, and interacts with subject on a regular basis~6. Ability of subject to swallow the compound~7. Stable concomitant medications for at least 2 weeks~8. No planned changes in psychosocial interventions during the open-label N-Acetyl Cysteine trial~Exclusion Criteria:~1. DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified~2. Prior adequate trial of N-Acetyl Cysteine~3. Active medical problems: unstable seizures, significant physical illness (e.g., serious liver or renal pathology)~4. Pregnancy or sexually active females~5. Subjects taking antioxidant agents and glutathione prodrugs will be excluded from the study except if they have been off these compounds for at least 4 weeks

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Cysteine (Type: ACTIVE_COMPARATOR): active compound N-Acetyl Cysteine
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo or sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).